https://www.selleckchem.com/products/2-d08.html
Biomarker-driven therapies have not been developed for infant medulloblastoma (iM. We sought to robustly sub-classify iMB, and proffer strategies for personalized, risk-adapted therapies. We characterized the iMB molecular landscape, including second-generation subtyping, and the associated retrospective clinical experience, using large independent discovery/validation cohorts (n=387). iMB (42%) and iMB (40%) subgroups predominated. iMB harboured second-generation subtypes II/III/IV. Subtype II strongly associated with large-cell/anapla
Like
Comment
Share
